Monrovia, CA, August 21, 2008 --(PR.com
)-- Dr. Stanley Deresinski, Clinical Professor of Medicine-Med/Infectious Diseases at Stanford University in Palo Alto, CA will speak on “The Seemingly Never-ending Promise of Bacteriophage Therapy: Exploiting Smaller Fleas” at GTCbio’s Bugs & Drug Conf. on Sept. 22-23, 2008 at the DoubleTree Club Hotel in San Diego, CA.
Dr. Deresinski will speak on the renewed interest in Phage Therapy. Administration of phage may involve topical application (including aerosol), oral,and parenteral administration.. Since phage specifically replicate at the site of infection, small doses and single administrations may be sufficient. This replicative characteristic, together with the fact that most phage are rapidly cleared by the reticuloendothelial system, contribute to the unusual pharmacokinetic characteristics of phage, which do not resemble those of small molecules. The unusual pharmacokinetics may contribute to the regulatory uncertainty which is an important obstacle to the ultimate approval of systemic use of phage in humans. Another important regulatory obstacle is the need in some circumstances to overcome phage target specificity by their administration in combination. Potential barriers to the efficacy of phage therapy, such as whether intracellular location of bacteria or their growth in biofilm impede its activity, require further exploration. In addition, bacterial resistance to phage occurs at a frequency similar to that of resistance to many antibiotics.
While lytic phage are themselves lethal to bacteria, the use of phage as a delivery system for drugs, toxins and antibody has also been explored. Phage may also prove to be effective carriers of peptide and DNA vaccines. Administration of phage lysin, which allows the phage to degrade bacterial peptidoglycan, has been effective in animal models of infection. In the preclinical setting, phage may prove useful in identifying bacterial targets of novel antimicrobials and also serve as a means of rapid precise etiologic diagnosis of bacterial infections, with simultaneous susceptibility testing.
GTCbio’s Bugs & Drugs conference brings together top industry leaders including directors, vice presidents, heads, managers, supervisors, from all over the world to collaborate and discuss novel approaches to problematic pathogens for community-acquired Infections and hospital-acquired infections, contingency plans for biological weapons and disease outbreaks, the changing landscape of antibacterial development - politics vs. commerce, and the future of infectious disease therapeutics. For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/conferenceDetails.aspx?id=129.
GTCbio organizes conferences specifically for the biomedical and biopharmaceutical industries. Our goal is to facilitate the exchange of biopharmaceutical and biomedical intelligence between industry leaders, academic and government organizations, and the financial community.
GTCbio is a subsidiary of Global Technology Community, LLC, a privately held company founded in 2002.
Contact: GTCbio 434 W. Foothill Blvd. Monrovia, CA 91016 Tel: (626) 256-6405 fax: (626) 256-6460 email: email@example.com